Literature DB >> 16207569

HIV and liver diseases: recent clinical advances.

Cem Cengiz1, James S Park, Neeraj Saraf, Douglas T Dieterich.   

Abstract

Because the life expectancy of patients infected with HIV has been prolonged, liver diseases have assumed far greater importance as a cause of morbidity and mortality in these patients. Given the shared risks of transmission, patients who have HIV often are coinfected with hepatotrophic viruses such as hepatitis C and hepatitis B. Further, antiretroviral therapy (ART) used by patients who have HIV is often hepatotoxic, contributing to liver damage. With increasing immunosuppression caused by AIDS, patients who have HIV have to deal with these issues and the increased risk of infection with opportunistic viral, fungal, bacterial, and protozoal pathogens. In addition, steatosis and lipodystrophy now are recognized more commonly in patients who have HIV, particularly in the setting of ART. Thus, understanding of liver diseases in the setting of HIV infection becomes an important focus in caring these individuals. There have been numerous advances in the treatment of liver disease in patients who have HIV, particularly in treating viral hepatitis C and B. This article reviews various liver manifestations in patients who have HIV and the recent advances in diagnostic and therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207569     DOI: 10.1016/j.cld.2005.07.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Treatment Issues in Patients With HIV/HCV Co-Infection.

Authors:  Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-10

2.  Population-based biochemistry, immunologic and hematological reference values for adolescents and young adults in a rural population in Western Kenya.

Authors:  Clement Zeh; Pauli N Amornkul; Seth Inzaule; Pascale Ondoa; Boaz Oyaro; Dufton M Mwaengo; Hilde Vandenhoudt; Anthony Gichangi; John Williamson; Timothy Thomas; Kevin M Decock; Clyde Hart; John Nkengasong; Kayla Laserson
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

Review 3.  Therapeutic issues in HIV/HCV-coinfected patients.

Authors:  M S Sulkowski; Y Benhamou
Journal:  J Viral Hepat       Date:  2007-06       Impact factor: 3.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.